PUBLICATIONS (last updated 10-10)

Published Books

1.  Kradin RL, Robinson BWS.  Immunopathology of Lung Disease.  Butterworth-Heinemann, Boston. 1996.  [ISBN: 0-7506-9282-0]

2.    Robinson BWS, Chahinian P.  Mesothelioma.  Martin Dunitz.  2002. [ISBN:9-05823-180-1].

3.    Robinson BWS.  Fathering from the Fast Lane.  Finch Publishing, Sydney.  2002.  [ISBN:1-876451-21-1].

4.    Robinson,  Bruce. The Blue Book of Tips for Fathers and Father Figures. 2007. MACSIS Publishing, Perth.

5.    Robinson, Bruce. Daughters and their Dads. 2008.  MACSIS Publishing, Perth.

Published Case Reports and Letters

1.   Robinson BWS.  Henoch‑Schonlein purpura due to food sensitivity. Br Med J 1977; 1: 510‑511.

2.   Robinson BWS, Corless D.  Spurious polycythaemia resolving during observation. Br Med J 1978; 2: 280.

3.   Robinson BWS. Medical screening of old people.  Lancet 1978; 2: 532.

4.   Robinson BWS. Death from asthma.  Med J Aust 1980; 1: 144.

5.   Robinson BWS, Joske RA. Familial Mediterranean fever in Australia.. Med J Aust 1980; 1: 494.

6.   Robinson BWS. Bone‑scanning in hypertrophic osteoarthropathy.  Thorax 1980; 35:960.

7.   Robinson BWS. Lewis RR.  Myocardial metastasis from carcinoma of the pancreas presenting as acute myocardial infarction.  Proc Roy Soc Med 1982; 75: 560‑562.

8.  Robinson BWS. Doctor in pain-learning as a patient. Med J Aust 1992;156:669.

9.  Lee YC, Chew GT, Robinson BWS. Pulmonary and meningeal cryptococcisis in pulmonary alveolar proteinosis. Aust NZ J Med 1999, 29(6):843-4.

10.Robinson BWS, Lake RA. Malignant mesothelioma-reply. New England Journal of Medicine 354 (3):306-307 Jan 19 2006.

Book Chapters

1.  Lee J, Robinson BWS.  The history of mesothelioma in Australia 1945-2001. .  In: Mesothelioma.  Robinson BWS, Chahinian PA, Editors.  London: Martin Dunitz; 2002. p.55-86.

2.   Lee YC, Thompson RI, Dean A, Robinson BWS.  Clinical and palliative care aspects of malignant mesothelioma.  In: Mesothelioma.  Robinson BWS, Chahinian PA, Editors.  London: Martin Dunitz; 2002. p.111-126.

3.  Sterman DH, Albelda SM, Mukherjee S, Robinson BWS.  Gene therapy for malignant mesothelioma – “suicide gene” and immunological approaches. In: Mesothelioma.  Robinson BWS, Chahinian PA, Editors.  London: Martin Dunitz; 2002. p.223-234.

4.  McLaren B, Robinson BWS.  The molecular pathogenesis of mesothelioma. In: Mesothelioma.  Robinson BWS, Chahinian PA, Editors.  London: Martin Dunitz;  2002. p.307-323.

5.  Mukherjee S, Robinson BWS.  Immunotherapy of malignant mesothelioma. In: Mesothelioma.  Robinson BWS, Chahinian PA, Editors.  London: Martin Dunitz; 2002. p.325-338.

6.  McLaren BR, Robinson BWS, Lake RA.  Pathogenesis of mesothelioma.  Text book of Respiratory cell and molecular biology.  Wardlaw AJ and Hamid Q, Editors.  London: Martin Dunitz; 2002. p.367-380.

7.  Robinson BWS. Mesothelioma. in ‘Encyclopedia of Respiratory Medicine’ Geoffrey J. Laurent GJ, Shapiro S Eds. 2006. Elsevier. Oxford. 52-56.

8.   Nelson, D. Robinson BWS. Lake, R. Experimental models of mesothelioma. In Textbook of Pleural Diseases. Light, R. and Lee, Y. editors. Arnold, London, UK. 167-183.

9.   Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW.  Malignant mesothelioma: studies of immunological anti‑cancer processes.  In G Peters, Ed.  Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, chap 5.  1989. Garland Publishing Inc, New York. 153‑172.

10.   Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW.  Evaluation of pulmonary inflammatory processes in asbestos‑exposed individuals.  In G Peters, Ed. Source Book on Asbestos Diseases; Vol 4, Asbestos Medical Research, 1989. chap. 9  Garland Publishing Inc, New York. 277‑296.

11.   Robinson BWS, Manning LS, Bowman RV, Whitaker D, Flexman J, Musk AW.  Malignant mesothelioma: studies of immunological anti‑cancer processes.  In “Asbestos Diseases Update”, Chap, 4.  Garland Publishing Inc, New York, 1989.

12.   Robinson BWS, Rose AH, Hayes A, Bowman RV, Musk AW.  Pulmonary inflammation in asbestos‑exposed individuals.  In “Asbestos Diseases Update”, Chap 1.  Garland Publishing Inc, New York, 1989.

13.   Whitaker DW, Manning LS, Robinson BWS , Shilkin K.  The pathobiology of the mesothelium. In Henderson DW, Shilkin K, Langlois S, Whitaker D  eds. Malignant Mesothelioma.  1992.  Hemisphere Publishing Corp. New York.  25‑68

14.   Robinson BWS, Manning LS, Christmas TI, Bowman RV, Davis MR, Musk AW.  Immunotherapy of malignant mesothelioma:  Studies using IL2/LAK cells and interferon alpha 2a.  In Hersey P Ed. Biological Agents in the Treatment of Cancer.  New South Wales Government Printing Office, Sydney, 1990; 414-423.

15.   Manning LS, Rose, AH, Bowman RV, Christmas TI, Garlepp MJ, Robinson BWS. Immune function related to asbestos exposure and mesothelioma, and immunotherapy of mesothelioma.  In Henderson DW, Shilkin K, Langlois S, Whitaker D, eds.  Malignant Mesothelioma.  1992.  Hemisphere Publishing Corp. New York. 278-291.

16.   Robinson BWS.  Cell reactions and inflammation.  In Rylander R, Jacobs RR, eds.  Handbook on Organic Dusts.  1994, CRC Press, Boca Raton Florida, 95-107.

17.   Garlepp MJ, Fitzpatrick D, Mutsaers S, Bielefeldt-Ohmann H, David M, Robinson BWS Mesothelioma: recent studies of growth regulation.  In G Peters (ed): Sourcebook on Asbestos Diseases; vol 8, 1993 Garland publishing Inc, New York. 201-218.

18.   Upham J, Musk AW, Robinson BWS  Mesothelioma: new therapeutic approaches.  In G Peters (ed):  Sourcebook on Asbestos Diseases; vol 8, 1993 Garland publishing Inc, New York.  191-200.

19.   Robinson BWS.  Immunobiology and immunotherapy of malignant mesothelioma.  In: Mesothelial Cell and Mesothelioma, J Bignon, MC Jaurand (eds).  Lung Biology in Health and Disease, Volume 78.  New York 1994; 253-266.

20.   Robinson BWS, Davidson JA, Garlepp MJ.  The immunology and immunopathology of malignant mesothelioma.  Kradin RL, Robinson BWS eds.  In: Immunopathology of lung disease.  Butterworth Heinemann, Stoneham, MA 1996:91-513.

21.   McLennan G, Walsh RL, Robinson BWS.  Bronchalveolar Lavage.  Kradin RL, Robinson BWS eds.  In: Immunopathology of lung disease.   Butterworth Heinemann, Stoneham, MA 1996:529-540.

22.   Robinson BWS, Sellner L, Redwood A, Leong CC, Davidson JA, Peroni DJ, Marzo AL, Garlepp MJ and Scot B.  New techniques for evaluating lung immunology and immunopathology.  Kradin RL, Robinson BWS eds.  In: Immunopathology of lung disease.  Butterworth Heinemann, Troneham, MA 1996:541-567.

23.   Robinson BWS.  Sarcoidosis,  Kradin RL, Robinson BWS eds.  In: Immunopathology of lung disease.  Butterworth Heinemann, Stoneham, MA 1996:165-190.

24.   Robinson BWS, Garlepp MJ, Scott B.  Mesothelioma.  In Crystal RG, West JB. Eds.  The Lung: Scientific Foundations, Second Edition, 1995.  Raven Press, New York 2599-2610.

25.   Garlepp MJ, Davidson JA, Leong CC, Robinson BWS  Gene therapy of malignant mesothelioma.  In: The internet book of gene therapy: cancer therapeutics.  Eds. Sobol RE, Scanlon KJ, Appleton & Lange, Norwalk, CT, pp 257-268, 1995.

26.   Davidson JA, Robinson BWS,.  Mesothelioma.  Stuart-Harris R, Penny R eds.  In, The Clinical Applications of the Interferons, 1995:225-235.

27.   Scott B, Mukherjee S, Lake R, Robinson BWS,  Malignant Mesothelioma.  In: Textbook of Lung Cancer. Ed Hanson H.  London: Martin Dunitz; 2000.p.273-293.

28.   McLaren B, Robinson BWS,.  Pathogenesis of Mesothelioma.  In: Textbook of Respiratory Cell and Molecular Biology.  Eds Hamid Q, Wardlaw AJ, Harwood Academic Publishers 2002.p.367-380.

29.   Nelson D, Lake RA, Robinson BWS. Experimental models of mesothelioma. In: Textbook of Pleural Diseases.  Eds. Light RW and Lee YCG; 2003. 167-179

30.   Nowak AK, Lake RA, and Robinson BWS.  Immunotherapeutic Approaches and Vaccination Strategies. In: Malignant Mesothelioma. Eds. Pass, Vogelzang, Carbone, 2005. 798-817

31.   Robinson BWS. Malignant Mesothelioma. In: Encyclopaedia of Respiratory Medicine. Eds. Laurent GJ, Shapiro SD. Elsevier Ltd. 2006, 52-56.

32.   Nelson D, Robinson C, Dunham MA, Robinson BWS. Malignant Mesothelioma. In: Environmental and Occupational Medicine. Eds. Rom WN, Markowitz SB, 2007. 317-329

33.   Smith AM,  Lansley S, Jackaman C, Koloska B. Broomfield S, Robinson BWS, Nelson DJ. Immunobiology of Malignant Mesothelioma (MM). In: Malignant Pleural Mesothelioma.  Eds. O’Byrne K, Rusch V.  Oxford University Press, USA,. 2007

34.   Robinson BWS, Lake R, Robinson C, Creaney J. Malignant Mesothelioma In: Textbook of Lung Cancer.  2nd Edition. Ed. Hanson H.  London: Dunitz M. 2008.

35.   Creaney J, Robinson BWS. Possible Roles for Soluble Mesothelin-Related Proteins as Tumour Markers for Malignant Mesothelioma. In: Mesothelioma form bench to clinic. Editor: Alfonso Baldi, © 2007 Nova Science Publishers, Inc.

Published Papers

1.   Robinson BWS, Musk AW.  Benign asbestos pleural effusion diagnosis and course.  Thorax 1981; 36: 896 900.

2.   Robinson BWS.  Nitrofurantoin induced interstitial pulmonary fibrosis.  Med J Aust 1983; 1: 72 76.

3.   Robinson BWS, Pinkston P, Crystal RG.  Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest 1984; 74: 942‑50.

4.   Venet A, Hance AJ, Saltini C, Robinson BWS, Crystal RG.  Enhanced alveolar macrophage‑mediated antigen induced T lymphocyte proliferation in sarcoidosis.  J Clin Invest 1985; 75: 293‑301.

5.   Robinson BWS, McLemore TL, Crystal RG.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.  J Clin Invest 1985; 75: 1488‑1495.

6.   Robinson BWS, Rose AH, Hey A, Whitaker D, Musk AW.  Alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite‑ and chrysotile‑exposed individuals.  Chest 1986; 90: 396‑402.

7.   Holt P, Robinson BWS , Reid M, Kees U, Warton A, Dawson V, Rose AH,   Schon‑Hegrad M, Papadimitrou J.  Extraction of immune and inflammatory cells from human lung parenchyma: evaluation of an enzymatic  digestion procedure.   Clin Exp Immunol 1986; 66: 188‑200

8.   Robinson BWS, Morstyn G.  Interleukin‑2‑activated Natural Killer cells are active against lung cancer cells. Chest 1987; 91: 31‑32.

9.   Robinson BWS, Rose A, Thompson PJ, Hey A.  Comparison of bronchoalveolar lavage helper/suppressor T-cell ratios in sarcoidosis versus other interstitial lung diseases.  Aust NZ J Med 1987; 17: 9‑15.

10. Robinson BWS.  Evaluation of pulmonary anti‑cancer and inflammatory processes in humans. MD Thesis. 1987. Uni of W Australia.

11. Robinson BWS, Morstyn G.  Natural killer (NK)‑resistant human lung cancer cells are lysed by recombinant interleukin‑2‑activated NK cells.  Cell Immunol 1987; 106: 215‑222.

12. Robinson BWS, James A, Rose A, Sterret G, Musk AW.  Bronchoalveolar lavage sampling of airway and alveolar cells.  Br J Dis Chest 1988; 82: 45‑55.

13. Robinson BWS, Rose AH, Hayes A, Musk AW.  Increased pulmonary gamma interferon production in asbestosis.  Am Rev Respir Dis 1988; 138:  278‑283.

14. Robinson BWS. Production of plasminogen activator by alveolar macrophages in normal subjects and patients with interstitial lung diseases.  Thorax 1988; 43:  508‑515

15. Holt PG, Kees UR, Schon‑Hegrad MA, Rose A, Ford J, Bilyk N, Bowman R, Robinson BWS. Limiting dilution analysis of T cells extracted from solid human lung tissue: comparison of precursor frequencies for proliferative responses and lymphokine production between lung and blood T cells from individual donors.  Immunology 1988; 64: 649‑654.

16. Hayes A, Rose AH, Musk AW, Robinson BWS. Neutrophil chemotactic factor release and neutrophil alveolitis in asbestos‑exposed individuals.  Chest 1988; 94:  521‑525.

17. Warton A, Papadimitriou JM, Venaille TJ, Mendis SHW, Robinson BWS.  Human amnion membrane as a model for studying the host‑parasite relationship in trichomoniasis.  Int J Parasitol 1988; 18: 1003‑1005.

18. Robinson BWS, Kees UR, Holt PG.  Lung interstitial natural killer cells in patients with lung cancer:  presence, activity and response to interleukin‑2.  Lung Cancer 1989; 5: 41‑48.

19. Hayes A, Mullan B, Lovegrove FT, Robinson BWS , Musk AW.  Gallium lung scanning and bronchoalveolar lavage in crocidolite‑exposed workers.  Chest 1989; 96: 22‑26.

20. Manning L, Bowman RV, Darby SB, Robinson BWS. Lysis of human malignant mesothelioma cells by natural killer (NK) and lymphokine‑activated killer (LAK) cells.  Am Rev Respir Dis, 1989; 139: 1369‑1374.

21. Gibson PG, Robinson BWS , McLennan G, Bryant DH, Breit SN.  The role of bronchoalveolar lavage in the assessment of diffuse lung diseases.  Aust NZ J Med 1989; 19: 281‑291

22. Robinson BWS.  Asbestos and cancer: human natural killer cell activity is suppressed by asbestos fibres but can be restored by recombinant interleukin‑2.  Am Rev Respir Dis, 1989; 139: 897‑901.

23. Venaille T, Mendis A, Warton A, Walker L, Papadimitriou J, Robinson BWS, Study of human epithelial cell detachment and damage: development of a model. Immunol Cell Biol 1989; 67: 359‑369. 

24. Mendis AHW, Venaille T, Robinson BWS. Study of human epithelial cell detachment and damage: effects of proteases and oxidants.  Immunol and Cell Biol 1990; 68:95‑105.

25. Hayes A, Venaille TJ, Rosse AH, Musk AW, Robinson BWS.  Asbestos‑induced release of a human alveolar macrophage-derived neutrophil chemotactic factor. Exp Lung Res 1990;16:121‑130.

26. Robinson BWS, Rose AH.  Pulmonary g interferon production in patients with fibrosing alveolitis.   Thorax 1990;45:105‑108.

27. Flexman J, Manning L, Robinson BWS.  In vivo boosting of lung natural killer and lymphokine‑activated killer cell activity by interleukin‑2:  Comparison of systemic, intrapleural and inhalation routes.  Clin Exp Immunol 1990; 82:151‑156.

28. Robinson BWS, Venaille TJ, Mendis AHW, McAleer R.  Allergens as proteases: an aspergillus fumigatus proteinase directly induces human epithelial cell detachment.  J Allergy Clin Immunol 1990; 86:726‑731.

29. Phillips MJ, Venaille TJ, Mendis AHW, Thompson PJ, Robinson BWS  Effect of nedocromil sodium on neutrophil and eosinophil‑induced epithelial cell desquamation in a human in vitro epithelial model.  Drugs 1989; 37: 56‑62.

30. Manning LS, Bowman RV, Davis MR, Musk AW, Robinson BWS.  Indomethacin augments lymphokine‑activated killer cell generation by patients with malignant mesothelioma.  Clin Immunol and Immunopath 1989; 53: 68‑77.

31. Robinson BWS. After the Fellowship ‑ basic research Med J Aust 1990;153:692‑696

32. Bowman R, Manning LS, Davis M, Robinson BWS Capacity of tumour necrosis f factor to augment lymphocyte-mediated tumor cell lysis of malignant mesothelioma.  Clin Immunol Immunopath 1991;58:80‑91

33. Manning LS, Murch A, Garlepp MJ, Davis MR, Musk A, Robinson BWS.  Establishment and characterisation of five human malignant mesothelioma cell lines derived from pleural effusions. Int J Cancer 1991;47:285‑290

34. Manning L, Davis M, Robinson BWS  Asbestos fibres inhibit the in vitro activity of lymphokines-activated killer (LAK) cells from healthy individuals and patients with malignant mesothelioma.  Clin Exp Immunol 1991;83:85‑91.

35. Robinson BWS, Bowman R, Christmas T, Musk AW, Manning LS.  Immunotherapy for malignant mesothelioma: use of interleukin‑2 and interferon alpha. Interferons and Cytokines 1991;18:5‑7.

36. Robinson BWS, Sterrett G.  Bronchiolitis obliterans associated with polyarteritis nodosa.  Chest 1992 102:309-311

37. Christmas TI, Manning LS, Davis MR, Robinson BWS, Garlepp M.  HLA antigen expression and malignant mesothelioma. Am J Resp Cell Mol Biol. 1991;5:213‑220.

38. Bowman R, Whitaker D, Manning LS, Davis MR, Robinson BWS  Interaction between Dactinomycin and tumor necrosis factor in mesothelioma ‑ cachexia without oncolysis.  Cancer 1991;67:2495‑2500.

39. Bowman R, Manning LS, Davis MR, Robinson BWS  Chemosensitivity and cytokine sensitivity of malignant mesothelioma.  Cancer Chemother Pharmacol 1991;28:420‑426.

40. Robinson BWS.  Organic dust disease; mediators and mechanisms.  In: Rylander R and Musk AW (eds).  Workshop on Health Effects of Grain and Other Organic Dusts, Committee on Organic Dusts, ICOH,  26‑29.

41. Robinson BWS.  Doctor in pain - learning as a patient.  Med J Aust 1992 156:355-357

42. Robinson BWS, Venaille T, Blum R, Mendis AH.  Eosinophils and major basic protein damage but do not detach human amniotic epithelial cells. Exp Lung Res 1992;18:583-593

43. Holt PG, Clough JB, Holt BJ, Baron-Hay MJ, Rose AH,  Robinson BWS Thomas WR. Genetic 'risk' for atopy is associated with delayed postnatal maturation of T-cell competence.  Clin Exp Allergy 1992;22:1093-99.

44. Davis MR, Manning LS, Whitaker D, Robinson BWS.  Establishment of a murine model of malignant mesothelioma.  Int J Cancer  1992 52:881-886.

45. Garlepp MJ, Rose AH, Bowman RV, Mavaddat N, Dench J, Holt BJ, Baron‑Hay M, Holt PG, Robinson BWS.  A clonal analysis of lung T cells derived by bronchoalveolar lavage of healthy individuals.  Immunology 1992 77:31-37

46. Christmas TI, Manning LS, Garlepp MJ, Musk AW, Robinson BWS.  Effect of Interferon a-2a on malignant mesothelioma. J Interferon Res 1993;13:9-12.

47. Manning LS, Davis MR, Bielefeldt‑Ohmann H, Marzo AL, Garlepp MJ, Whitaker D, Robinson BWS  Evaluation of immunogenicity of murine mesothelioma cells by immunization.  Europ Resp Rev 1993;3(11):234-237.

48. Robinson BWS, Bowman RV, Manning LS, Musk AW, Van Hazel GA.  Interleukin‑2 and lymphokine‑activated killer cells in malignant mesothelioma.  Europ Resp Rev; 1993;3(11):220-222.

49. Garlepp MJ, Christmas TI, Manning LS, Davis MR, Robinson BWS  Constitutive and inducible HLA antigen expression in malignant mesothelioma.  Europ Resp Rev 1993 3:11:231-233.

50. Garlepp MJ, Christmas TI, Mutsaers SE, Manning LS, Davis M, Robinson BWS  Platelet‑derived growth factor as an autocrine factor in murine malignant mesothelioma.  Europ Resp Rev 1993;3(11):192-194.

51. Garlepp MJ, Christmas TI, Manning LS, Mutsaers S, Dench J, Leong C, Robinson BWS. The role of platelet-derived growth factor in the growth of human malignant mesothelioma.  Eur Respir Rev 1993;3(11):189-191.

52. Robinson BWS, Manning LS, Bowman RV, Christmas TI, Musk AW, Davis MR, Bielefeldt‑Ohmann H, Upham J, Garlepp MJ.  The scientific basis for the immunotherapy of human malignant mesothelioma.  Europ Resp Rev 1993;3(11):195-198.

53. Mavaddat N, Robinson BWS, Rose AH, Manning LS, Garlepp MJ.  An analysis of the relationship between SYMBOL 103 \f "Symbol"SYMBOL 100 \f "Symbol" T cell receptor V gene usage and non-major histocompatability complex-restricted cytotoxicity.  Immunol & Cell Biol 1993 71:27-37.

54. Davis M, Manning LS, Whitaker D, Garlepp MJ, Robinson BWS  A murine model of mesothelioma.  Eur Respir Rev 1993;3(11):116-117.

55. Upham J, Garlepp MJ, Musk AW, Robinson BWS  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.  Thorax 1995;50:887-893.

56. Robinson BWS.  Development of new therapeutic strategies for mesothelioma.  Lung Cancer 1993;9:413-418.

57. Upham JW, Musk AW, van  Hazel G, Byrne M, Robinson BWS  Interferon alpha and doxorubicin in malignant mesothelioma.  Aust NZ J Med 1993;23:683-687.

58. Robinson BWS.  Immunotherapy strategies in patients with mesothelioma. Cancer Forum 1993;17:106-111.

59. Venaille TJ, Musk AW, Robinson BWS  Direct effects of selected occupational asthma-inducing agents on human epithelial cells.  J Occup Health Safety 1993;9:435-446.

60. Garlepp MJ, Dench JE, Rose AH, Robinson BWS  Clonal analysis of lung and blood T cells in patients with sarcoidosis.  Thorax 1994;49:577-585.

61. Upham JW, McMenamin C, Schon-Hegrad MA, Robinson BWS ,Holt PG.  Functional analysis of human bronchial mucosal T cells extracted with Interleukin-2.  Am J Respir Crit Care Med 1994;149:1608-1613.

62. Richardson DR, Cameron K, Robinson BWS ,Turner KJ.  The mechanisms of IgE uptake by human alveolar macrophages and a human B-lymphoblastoid cell line (Wil-2wt).  Immunology 1993;79:305-311.

63. Christmas TI, Manning LS, Mutsaers SE, Dench J, Leong C, Robinson BWS Garlepp MJ.  Platelet‑derived growth factor as an autocrine factor in murine malignant mesothelioma.  Eur Respir Rev 1993;3(11):192-194

64. Venaille TJ, Misso NLA, Phillips MJ, Robinson BWS ,Thompson PJ.  Effects of different density gradient separation techniques on neutrophil function.  Scand J Clin Lab Invest 1994:54;385-391

65. Leong C, Robinson BWS , Garlepp M.  Generation of an antitumour immune response to a murine mesothelioma cell line by the transfection of allogeneic MHC genes. Int J Cancer 1994;59:212-216.

66. Venaille TJ, Mendis AHW, Phillips MJ, Thompson PJ, Robinson BWS.  Role of neutrophils in mediating human epithelial cell detachment from native basement membrane.  J Allergy Clin Immunol 1995:95;597-606.

67. Staton JM, Dench JE, Currie B, Fitzpatrick DR, Himbeck R, Allen R, Bruce J, Robinson BWS , Bielefeldt-Ohmann H.  Expression and immune recognition of stress proteins in sarcoidosis and other chronic interstitial lung diseases.  Immunol Cell Biol 1995;73:23-32.

68. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS.  Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma.  Growth Factors 1994;11:29-44.

69. Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS, Robinson BWS,.  Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leukocytes and cytokine production in a murine model.  Cancer Immunol, Immuno 1994;39:347-359.

70. Upham JW, Strickland DH, Bilyk N, Robinson BWS, Holt PG.  Alveolar macrophages from humans and rodents selectively inhibit T-cell proliferation but permit T-cell activation and cytokine secretion.  Immunol 1995;84:142-147.

71. Bielefeldt-Ohmann H., Fitzpatric DR., Marzo AL., Jarnicki AG., Musk AW., Robinson BWS Potential for Interferon-a-based therapy in mesothelioma: assessment in a murine model.  J Interferon Cytokine Res 1995;15:213-223.

72. Bielefeldt-Ohmann H., Marzo AL., Himbeck RP., Jarnicki AG., Robinson BWS ,Fitzpatrick DR.  Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy.  Cancer Immunol, Immuno 1995;40:241-250.

73. Fitzpatrick DR, Manning LS, Musk AW, Robinson BWS, Bielefeldt-Ohmann H.  Potential for cytokine therapy of malignant mesothelioma.  Cancer Treatment Rev 1995;21:273-288.

74. Upham JW., Holt BJ., Baron-Hay MJ., Yabuhara A., Hales BJ., Thomas WR., Loh RKS., O'Keefe P., Palmer L., LeSouef P., Sly PD., Burton PR., Robinson BWS., Holt PG.  Inhalant allergen-specific T cell reactivity is detectable in close to 100% of atopic and normal individuals: covert responses are unmasked by serum-free medium.  Clin Exp Allergy 1995;24:634-642.

75. Jarnicki AG, Fitzpatrick DR, Robinson BWS, Bielefeldt-Ohmann H.  Altered CD3 chain and cytokine gene expression in tumour infiltrating T lymphocytes (TIL) during the development of mesothelioma.  Cancer Lett 1996;103:1-9.

76. Leong CC, Marley JV, Loh S, Robinson BWS, Garlepp MJ.  Induction and maintenance of T cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.  Cancer Gene Therapy 1996;3:321-330.

77. Venaille TJ, Ryan G., Robinson BWS,.  Epithelial cell damage is induced by neutrophil-derived, not pseudomonas-derived, proteases in cystic fibrosis sputum.  Resp Med 1998:92;233-240.

78. Robinson BWS, Venaille TJ, Musk AW.  Effects of a selection of asthma-inducing occupational agents on human epithelial cells.  In Research Report 1994-95.  National Occupational Health & Safety Commission, Australian Govt. Printing Office, Canberra.  129-131.

79. Leong CC, Marley JV, Loh S, Robinson BWS , Garlepp MJ.  The induction of immune responses to murine malignant mesothelioma by IL-2 gene transfer.  Immunol and Cell Biol 1997:75;356-359.

80. Leong CC, Marley JV, Loh S, Robinson BWS , Garlepp MJ.  Transfection of the gene for B7-1 but not B7-2 can induce immunity to murine malignant mesothelioma.  International J Cancer 1996;71:476-482.

81. Davidson JA, Musk AW, Wood Baker R, Morey S, Ilton M, Yu LL, Drury P, Shilkin K, Robinson BWS,  Intralesional cytokine therapy in cancer; A pilot study of GM-CSF infusion in mesothelioma.  J Immunotherapy 1998;21:389-398.

82. Marzo AL, Fitzpatrick DR, Robinson BWS , Scott B., Antisense oligonucleotides specific for transforming growth factor b2 inhibit the growth of malignant mesothelioma both in vitro and in vivo.  Cancer Research 1997;57:3200-3207.

83. Upham JW, Strickland DH,  Robinson BWS, Holt PG.  Selective inhibition of T cell proliferation but not expression of effector function by human alveolar macrophages.  Thorax 1997;52:786-795.

84. Robinson BWS, Mukherjee S, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi I, Scott B.  Cytokine gene therapy or infusion as treatment for solid human cancer.  J Immunotherapy 1998;21(3):211-217.

85. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Scott B, Robinson BWS,  Interleukin-12 induces an effective anti-tumour response in malignant mesothelioma.  Am J Resp Cell Mol Biol 1998;19(5):738-46.

86. Robinson C, Robinson BWS , Lake RA.  Sera from patients with malignant mesothelioma contain autoantibodies.  Lung Cancer.  1998;20(3):175-84

87. Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH,. Robinson BWS,  Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.  J Clin Onc 1999;17:25-30.

88. Lake RA, Robinson BWS, Hayball JD.  MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response.  Immunol Cell Biology.  1999  77(1):99-104.

89. Marzo AL, Lake RA, Robinson BWS Scott B  T-Cell Receptor Transgenic Analysis of Tumor-specific CD8 and CD4 responses in the eradication of solid tumours.  Cancer Res.  1999;59:1071-1079.

90. Pass HI, Robinson BWS , Testa JR, Carbone M.  Emerging translational therapies for mesothelioma.  Chest 1999;116:455S-460S

91. Marzo AL, Lake RA, Lo D, Sherman L, McWilliam A, Nelson D, Robinson BWS , Scott B.  Tumor antigens are constitutively presented in the draining lymph nodes.  J Immunol 1999; 162:5838-5845.

92. Caminschi I, Venetsanakos E, Leong CC, Garlepp MJ, Robinson BWS, Scott B.  Cytokine gene therapy of mesothelioma:  Immune and anti-tumor effects of transfected IL12.  Am J Resp Cell Mol Biol. 1999, 21(3):347-356.

93. Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson BWS, Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Therapy.  2000,7(5):663-670. (IF 2.756)

94. Robinson BWS, Lake RA, Nelson DJ, Scott BA, Marzo AL.  Cross-presentation of Tumour Antigens – Evaluation of Threshold, Duration, Distribution and Regulation.  Immunol. Cell Biol.  1999:77:552-558. (IF 2.665)

95. Robinson C, Callow M, Stevenson S, Scott B, Robinson BWS , Lake RA.  Serologic responses in patients with malignant mesothelioma: evidence for both public and private specificities.  Am J. Respir. Cell Mol. Biol.  2000;22:550-556. (IF 4.163)

96. McLaren BR, Robinson BWS , Lake RA.  New chemotherapeutics in malignant mesothelioma:  Effects on cell growth and IL6 production.  Cancer Chemother Pharmacol.  2000;45(6):502-508. (IF 2.170)

97. Robinson BWS, Erle DJ, Jones DA, Shapiro S, Metzger WJ, Albelda S, Parks WC, Boylan A. Recent advances in molecular biological techniques and their relevance to pulmonary research.  Thorax 2000;55:329-339. (IF 4.090)

98. Robinson BWS, Scott BM, Lake RA, Stumbles PA, Nelson DJ, Fisher S, Marzo AL.  Lack of ignorance to tumor antigens: evaluation using nominal antigen transfection and T-cell receptor transgenic lymphocytes in Lyons-Parish analysis - implications for tumor tolerance.  Clin Cancer Res.  2001;7(3 Suppl):811s-817s. (IF 5.076)

99. McLaren BR, Haenel T, Stevenson S, Mukherjee S, Robinson BWS , Lake RA.  SV40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas.  .Aust NZ J Med.  2000;30(4):450-456. (IF 0.528)

100.  Robinson BWS, Robinson C, Lake R.  Localised spontaneous mesothelioma regression in mesothelioma – probable immunological mechanism.  Lung Cancer.  2001;32(2):197-201. (IF 2.915)

101.  Creaney J, McLaren BM, Musk AW, de Klerk N, Robinson BWS, Lake RA.  P53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.  BJ Cancer.  2001;84(1):52-56. (IF 3.942)

102.  Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, Robinson BWS , Scott B.  Tumor-Specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumour immunity.  J Immunol.  2000;165(11):6047-6055. (IF 7.065)

103.  Nelson DJ, Bundell C, Robinson BWS,.  In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.  J Immunol.  2000; 165:6123-6232. (IF 7.065)

104.  Nelson DJ, Mukherjee S, Bundell C, Fisher S, van Hagen D, Robinson BWS . Tumor progression despite efficient tumor antigen cross-presentation and effective “arming” of tumor antigen-specific CTL.  J Immunol.  2001;166:5557-5566. (IF 7.065)

105.  Mukherjee S, Nelson DJ, Loh S, van Bruggen I, Palmer LJ, Leong C, Garlepp MJ, Robinson BWS The immune anti-tumor effects of GM-CSF and B7-1 gene transfection are enhanced by surgical debulking of tumor.  Cancer Gene Therapy.  2001;8:580-588. (IF 2.756)

106.  Robinson C, Callow M, Stevenson S, Robinson BWS , Lake RA.  Private specificities can dominate the humoral response to self antigens in patients with cryptogenic fibrosing alveolitis.  Respiratory Research.  2001;2:119-124.

107.  Nowak A, Robinson BWS & Richard A Lake Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.  Cancer Research.  2002; 62(8) 2353-2358. (IF 8.302)

108.  Nowak A, Lake RA, Kindler HL, Robinson BWS  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents.  Seminars in Oncology.  2002 Feb;29(1):82-96 (IF 3.600)

109.  McLaren B, Whitaker D, Robinson BWS , Lake RA.  Expression and integrity of DNA topoisomerase II isoforms does not explain generic drug resistance in malignant mesothelioma.  Cancer Chemother Pharmacol.  2001;48(1):1-8. (IF 2.170)

110.  Nowak AK, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BWS,  A multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma.  British Journal of Cancer.  2002; 87:491-496. (IF 3.639)

111.  Nowak AK, Lake RA, Marzo AL, Scott B, Heath RW, Collins EJ, Frelinger JA,. Robinson BWS,  Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T-cells.  J Immunol.  2003; 170:4905-4913. (IF 6.702)

112.  Mukherjee S, Upham JW, Ramshaw I, Bundell C, van Bruggen I, Robinson BWS , Nelson DJ.  Dendritic cells infected with a vaccinia virus interleukin-2 vector secrete high levels of IL-2 and can become efficient antigen presenting cells that secrete high levels of the immunostimulatory cytokine interleukin-12.  Cancer Gene Therapy.  2003;10:591-602. (IF 3.688)

113.  Nowak AK, Robinson BWS , Lake RA.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.  Cancer Research.  2003;63:4490-4496. (IF 8.649)

114.  Jackaman C, Bundell C, Kinnear B, Smith A, Filion ,P, van Hagan, Robinson BWS D.Nelson Interleukin-2 intra-tumoral immunotherapy enhances CD8+ cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol.  2003;171:5051-5063. (IF 6.702)

115.  Hayball JD, Robinson BWS, Lake RA.  CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells.  Imm Cell Biol. 2004 Apr;82(2):103-11. (IF 2.618)

116.  Robinson BWS, Creaney J, Lake RA, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom E, Hellstrom I.  Mesothelin-family proteins and diagnosis of mesothelioma.  The Lancet 2003;362:1612-1616. (IF 18.316)

117.  Robinson BWS.  Soluble mesothelin-related protein – a sensitive new marker for mesothelioma.  Am J Oncol Rev. 2004;3:230-233.

118.  Nowak AK, Byrne MJ, Millward MJ, Alvarez JM, Robinson BWS  Current chemotherapeutic treatment of malignant pleural mesothelioma.  Expert Opinion in Pharmacotherapy. 2004;5(12):2441-2449. (IF 4.593)

119.  Robinson BWS, Edwards MG. Climbing Mount Kilimanjaro in a Blizzard. Med J Aust. 2004;181 (11/12): 646-648 (IF 2)

120.  Stumbles PA, Himbeck R, Frelinger JJ, Lake RA, Robinson BWS.  Tumour-specific CTL Are Constitutively Cross-Armed in Draining Lymph Nodes and Transiently Disseminate Tumor Regression following Systemic CD40 Activation. J Immunol. 2004;173:5923-5928. (IF 6.486)

121.  Robinson BWS, Musk AW, Lake RA.  Malignant Mesothelioma. The Lancet.2005 366:397-408 (IF 21.713)

122.  Lake RA, Robinson BWS,  Immunotherapy and chemotherapy- a practical partnership. Nature Rev Cancer.2005;5:397-405. (IF 36.557)

123.  Robinson BWS, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I.  Soluble mesothelin-related protein – A blood test for mesothelioma.  Lung Cancer 2005 49: S109-S111 (IF 2.914)

124.  Creaney J, Robinson BWS, Detection of mesothelioma in asbestos exposed individuals: The potential role of soluble mesothelin related protein.  Seminars in Haematology-Oncology. 2005 19:1025-40 (IF 2.393)

125.  van der Most, R.G., Robinson BWS, and Lake, R.A., Combining Immunotherapy With Chemotherapy to Treat Cancer. Discovery Medicine 2005; 5:265-70 (IF 3.727)

126.  Nelson DJ, Robinson BWS , Allan J, Van der Most R.  Gene therapy of mesothelioma. Expert Opin Biol Ther. 2005, 8:1039-49. (IF 2.446)

127.  van Bruggen I, Nelson DJ, Currie AJ, Jackaman C, Robinson BWS,  Intratumoral poly-N-acetyl glucosamine-based polymer matrix provokes a prolonged local inflammatory response that, when combined with IL-2, induces regression of malignant mesothelioma in a murine model. J Immunother. 2005 Jul-Aug;28(4):359-67. (IF 3.509)

128.  Broomfield S, Currie A, van der Most RG, Brown M, van Bruggen I, Robinson BWS , Lake RA. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 2005 Sep 1;65:7580-4 (IF 7.690)

129.  Robinson BWS, Lake RL. Advances in Malignant Mesothelioma. New Eng J Med 2005;353:1591-603 (IF 38.570)

130.  Bundell CS, Jackaman C, Suhrbier A, Robinson BWS, Nelson DJ. Functional endogenous cytotoxic T lymphocytes are generated to multiple antigens co-expressed by progressing tumors; after intra-tumoral IL-2 therapy these effector cells eradicate established tumors. Cancer Immunol Immunother. 2006 Aug;55(8):933-47.

131.  Van der Most RG, Currie A, Robinson BWS, Lake RA, Cranking the immunologic engine with chemotherapy: Using context to drive tumour antigen cross-presentation towards useful anti tumour immunity.  Cancer Research 2006 Jan 15 66(2):601-4 (IF 7.690)

132.  Van der Most RG, Robinson BWS, Nelson DJ. Gene therapy for malignant mesothelioma: beyond the infant years Cancer Gene Therapy  2006 Jan 27; 1-8 (IF 3.653)

133.  Zhong J, Gencay-Cornelson MM, Bubendorf L, Burgess JK, Parson H, Robinson BWS, Tamm M, Black JL, Roth M. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP and TIMP and affect cell migration: a comparison between mesothelioma and mesothelial cells. Journal of  Cellular Physiology 2006 May; 207(2):540-52 (IF 5.222)

134.  Powell A, Creaney J, Broomfield S, van Bruggen I, Robinson BWS,  Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma. Lung Cancer, 2006 Mar 22; 52,189-197 (IF 2.914)

135.  Holloway AJ, Diyagama DS, Opeskin K, Creaney J, Robinson BW, Lake RA, Bowtell DD. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clinical Cancer Res. 2006 Sep 1; 12 (17):5129-35  [IF: 5.175]

136.  Nowak AK, Lake RA, Robinson BW. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev. 2006 Oct 1;58(8):975-90. [IF: 7.189]

137.  Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, Robinson BW, Lake RA. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006 Nov 15;66(22):10786-94 [IF: 7.189]

138.  Creaney J, Christansen H, Lake RA, Musk A.W, de Klerk N, Robinson BWS. Soluble mesothelin related protein in mesothelioma. 2006 Journal of Thoracic Oncology. 2;172-174 [IF: 7.616]

139.  Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand M-C, Kjaerheim K, Pass HI, Robinson BWS, Tsao A. Outcomes from the Eighth International Mesothelioma Conference. Oncogene. 2007 Oct 25;26(49):6959-67.[IF:6.9]

140.  Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BWS. Soluble mesothelin in effusions – a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007 Jul;62(7):569-76. [IF:6.150]

141.  Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007 Oct;132(4):1239-46.

142.  van der Most RG, Currie AJ, Robinson BW, Lake RA. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 2008 Jan; 15(1):13-20.

143.  Creaney J, Segal A, Sterrett G, Platten MA, Baker E, Murch AR, Nowak AK, Robinson BW, Millward MJ. Overexpression and altered glycosylation of MUC1 in malignant mesothelioma. Br J Cancer. 2008;98(9):1562-9.

144.  Diyagama DS, Lake RA, Robinson BWS, Creaney J, Bowtell DDC, Holloway AJ. An integrated analysis of chromosomal alteration and gene expression in malignant mesothelioma. Lung Cancer 54: Suppl 1 October 2006 P523.

145.  Nelson D, Jackaman C, Robinson BWS, et al. Targeting the tumor microenvironment: A novel immunotherapy that cures large mesothelioma tumors by engaging neutrophils, CD8+T cells and tumor blood vessels. Lung Cancer 54: S12-S12 47 [IF: 3.554]

146.  Currie AJ, van der Most RG, Broomfield SA, Prosser AC, Tovey MG, Robinson BW. Targeting the Effector Site with IFN-{alpha}{beta}-Inducing TLR Ligands Reactivates Tumor-Resident CD8 T Cell Responses to Eradicate Established Solid Tumors. J Immunol. 2008 Feb 1;180(3):1535-44

147.  Park EK, Sandrini A, Yates DH, Creaney J, Robinson BW, Thomas PS, Johnson AR. Soluble mesothelin-related protein in an asbestos-exposed population: the dust-diseases board cohort study. Am J Respir Crit Care Med. 2008;178(8):832-7.

148.  Creaney J, Yeoman, D, Demelker, Y, Segal A, Musk, AW, Skates, SJ, Robinson BWS. Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma. Journal of Thoracic Oncology 2008 Aug; 3:8, 851-57.

149.  Jackaman C, Lew AM, Zhan Y, Allan JE, Koloska B, Graham PT, Robinson BW, Nelson DJ. Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008;20(11):1467-79.

150.  Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer. 2008; 61(2):235-43.

151.  Jackaman C, Cornwall S, Robinson BWS, Lew AM, Zhan Y, Nelson DJ. Local effector failure in mesothelioma is not mediated by CD4+CD25+Treg cells. European Respiratory Journal. 2009; 34: 162-175.

152.  van der Most RG, Currie AJ, Mahendran S, Prosser A, Darabi A, Robinson BW, Nowak AK, Lake RA. Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy. Cancer Immunol Immunother, Vol 58 no. 8 Aug 2009..

153.  Creaney J and Robinson BWS. Serum and pleural fluid biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine 2009 15:366-370.

154.  Currie AJ, Prosser A, McDonnell A, Cleaver AL, Robinson BW, Freeman GJ, van der Most RG. Dual control of antitumor CD8 T cells through the programmed death-1/programmed death-ligand 1 pathway and immunosuppressive CD4 T cells: regulation and counterregulation. J Immunol. 2009 Dec 15;183(12):7898-908.

155.  van der Most RG, Currie AJ, Cleaver AL, Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW, Smyth MJ, Scalzo AA, Degli-Esposti MA, Lake RA. Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth. PLoS One. 2009 Sep 10;4(9):e6982.

156.  Broomfield SA, van der Most RG, Prosser AC, Mahendran S, Tovey MG, Smyth MJ, Robinson BW, Currie AJ. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009 May 1;182(9):5217-24.

157. McDonnell AM, Prosser AC, van Bruggen I, Robinson BWS. Currie AJ. CD8α+ DCs are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor In press. European Journal of Immunology Accepted for publication 22.2.10

158. Kurts, C, Robinson BWS, Knolle PA. Cross-priming in health and disease. Nature Reviews Immunology, June 2010 10 (6): 403-414.

159. Creaney J, Musk AW, Robinson BW. Sensitivity of urinary mesothelin in patients with malignant mesothelioma. J Thorac Oncol. 2010 Sep;5(9):1461-6.

160. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson BW. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma. Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2238-46

161. Steer HJ, Lake RA, Nowak AK, Robinson BW. Harnessing the immune response to treat cancer. Oncogene. 2010 Sep 20. [Epub ahead of print].

Published Abstracts:

1.   Robinson BWS, Musk AW.  Benign asbestos pleural effusion. Aust NZ J Med 1981; 11: 340‑341.

2.   Robinson BWS, Pinkston P, Crystal RG.  Natural killer cells in the normal human lung are impotent due to local suppression but can be activated with interleukin‑2. Clin Res 1984; 32: 356. 

3.  Robinson BWS, Crystal RG.  NK cells are present but inactive in the normal human lung.   Am Rev Respir Dis 1984; 129: 7.  

4.   Robinson BWS, Crystal RG.  Chrysotile asbestos directly suppresses the activity of natural killer cells.   Am Rev Respir Dis 1984; 129: 7. 

5.  Robinson BWS, Crystal RG.  Spontaneous production of gamma interferon by lung immune cells in pulmonary sarcoidosis.   Aust NZ J Med 1985; 15: 491. 

6.  Robinson BWS, Pinkston P, Crystal RG.  The human lung exhibits low levels of natural killer cell defence activity.   Aust NZ J Med 1985; 15: 499. 

7.   Rom W, Robinson BWS , McLemore TL, Rose AH, Crystal RG.  Lung mononuclear cells from individuals with chronic inorganic dust exposure spontaneously release immune interferon.   Am Rev Respir Dis 1985; 131: 189. 

8.   Holt P, Robinson BWS , Kees U, Rose A.  Extraction of human lung interstitial cells using a slicing/enzyme digestion method.   Aust NZ J Med 1986; 16: 632.

9.   Robinson BWS, Rose AH, Musk AW.  Lung cells from some patients with chronic non‑granulomatous interstitial lung diseases spontaneously release gamma interferon.   Aust NZ J Med 1986; 16: 633.

10.   Robinson BWS, Rose A, Hey A, Whittaker D, Musk AW.  The alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite and chrysotile‑exposed individuals.   Aust NZ J Med 1986; 16: 634.

11. Hey A, Robinson BWS , Musk AW.  Neutrophil chemotactic factor is spontaneously released by alveolar macrophages in patients with asbestosis.   Aust NZ J Med 1986; 16: 628.

12.   Robinson BWS, Morstyn G.  Interleukin‑2‑activated natural killer cells are active against lung cancer cells. Aust NZ J Med 1986; 16: 621.

13.   Holt P, Kees U, Wharton A,.Robinson BWS  The human lung interstitium has a different cell profile to blood and alveolus.    Am Rev Respir Dis 1986; 133: 145.   

14.   Hayes A, Robinson BWS , Musk AW.  Neutrophil chemotactic factor is spontaneously released by alveolar macrophages in patients with asbestosis.   Am Rev Respir Dis 1986; 133: 198. 

15.   Musk AW, Robinson BWS , Rose AH, Hey A, Whitaker D.  The alveolitis of pulmonary asbestosis: bronchoalveolar lavage studies in crocidolite and chrysotile‑exposed individuals.   Am Rev Respir Dis 1986; 133: 199.  

16.   Robinson BWS, Morstyn G.  Human lung cancer cells can be destroyed by interleukin 2 (IL‑2) activated blood and lung natural killer (NK) cells.   Am Rev Respir Dis 1986; 133: 286.

17.   Robinson BWS, Rose AH, Musk AW.  Gamma interferon is a mediator of non‑granulomatous interstitial lung diseases.   Am Rev Respir Dis 1986; 133: 146. 

18.   James A, Rose A, Sterret G, Musk AW,. Robinson BWS  Accurate bronchoalveolar lavage (BAL) assessment of alveolitis requires separate processing of 'airway' and 'alveolar' samples.   Am Rev Respir Dis 1986; 133: 327. 

19.   Manning L, Hanks K,.Robinson BWS  Generation of lymphokine‑activated killer (LAK) cells for therapy of human malignancies:  comparison of different culture sera.  Aust NZ J Med 1987; 17: 513.

20.   Manning L, Robinson BWS  Human malignant ` cells are susceptible to lysis by interleukin‑2‑activated lymphokine‑activated killer (LAK) cells.   Aust NZ J Med 1987; 17: 515.

21.   Venaille T, Robinson BWS  Epithelium, inflammation and asthma:  a model for the study of epithelial cell detachment from basement membrane (BM).  Aust NZ J Med 1987; 17: 523.

22.   Mendis AHW, Venaille T, Vincent G,.Robinson BWS Biochemical mediators of epithelial cell damage.  Aust NZ J Med 1987; 17: 523.

23.   Blum GR, Venaille T, Mendis AHW,. Robinson BWS  Potential role of major basic protein (MBP) and other eosinophil‑derived proteins in asthma.  Aust NZ J Med 1987; 17: 514.

24.   Flexman J, Manning L, Robinson BWS.  Augmentation of lung natural killer (NK) cell activity by administration of recombinant inter‑ leukin‑2 (IL‑2): comparison of different routes of administration.  Aust NZ J Med 1987; 17: 515.

25.   Flexman J, Manning L,. Robinson BWS  Local therapy of pleural malignancy: evaluation of intrapleural interleukin‑2 (IL‑2) and/or lymphokine‑activated killer (LAK) cell administration.  Aust NZ J Med 1987; 17: 516.

26.   Hayes A, Musk AW, Lovegrove FT, Rose A, Ryan G,. Robinson BWS  Asbestos exposure and pulmonary gallium uptake.  Aust NZ J Med 1987; 17: 518.

27.   Rose AH, Whitaker D, Musk AW, Hayes A,.Robinson BWS  Evaluation of lung alveolar asbestos body (AB) load using bronchoalveolar lavage (BAL).  Aust NZ J Med 1987; 17: 519.

28.   Bowman R, Manning L,.Robinson BWS  Tumour necrosis factor (TNF) boosts lymphocyte‑mediated lysis of cultured and fresh human cancer cells.  Aust NZ J Med 1987; 17: 516.

29.   Holt PG, Kees U, Schon‑Hegrad M, Ford Y, Bilyck N and. RobinsonBWS  Functional studies on human T‑cells from solid lung tissue.  Aust NZ J Med 1987; 17: 513.

30.   Prichard MG, Naglan F, Rose A, Robinson BWS Lymphocytic broncho‑ alveolitis in patients with chronic cough.  Aust NZ J Med 1987; 17: 511.

31.   Mendis AH, Venaille T, McAleer R,. Robinson BWS  Pathogenic mechanisms underlying allergic bronchopulmonary fungal disease.  Aust NZ J Med 1988; 18: A527.

32.   Bowman R, Naplan, F, Rose A, Neates N, Musk AW,.Robinson BWS  Tumour necrosis factor in interstitial lung disease.  Aust NZ J Med 1988; 18: A527.

33.   Venaille T, Warton A, Phillips MJ, Robinson BWS , Thompson PJ.  Asthma mediators and epithelial cell membrane integrity.  Aust NZ J Med 1988; 18: A536.

34.   Rose AH, Musk AW, Neates N, Naglan F, Hayes A,. Robinson BWS  Asbestos exposure: evaluation of fibrotic, inflammatory and immunological processes in diseased v non‑diseased individuals.  Aust NZ J Med 1988; 18: A545.

35.   Neates N, Musk AW, Christiansen F, Hayes A, Robinson BWS.  Immunological profiles in subjects with crocidolite‑induced alveolitis.  Aust NZ J Med  1988; 18: A545.

36.   Manning LS, Bowman R, Darby S, Musk AW,.Robinson BWS  Lymphokine‑ activated killer (LAK) cells generated from patients with malignant mesothelioma (MM) are less effective against cultured MM cells than LAK cells from control individuals.   Aust NZ J Med 1988; 18: A553.

37.   Whitehead PR, Manning LS, Musk AW,. Robinson BWS  A low molecular weight immunosuppressive factor is present in the pleural fluid of patients with malignant mesothelioma (MM).  Aust NZ J Med 1988; 18: A553.

38.   Rose AH, Musk AW, Neates N, Hayes A,.Robinson BWS  Evaluation of fibrotic, inflammatory and immunological processes in asbestos exposed individuals.  Am Rev Respir Dis 1989; 4: A203.

39.   Manning LS, Bowman RV, Musk AW,.Robinson BWS  Patients with malignant mesothelioma (MM) demonstrate depressed lymphokine‑activated killer (LAK) cell activity: effects of imdomethacin (Indo), and intrapleural administration of interleukin‑2 (IL‑2) and LAK cells.  Am Rev Respir Dis 1989; 4: A213.

40.   Bowman R, Manning L, Davis M,.Robinson BWS  Profiles of drug and cytokine sensitivity of mesothelioma cell lines.  Am Rev Respir Dis 1989; 4: A219.

41.   Robinson BWS, Venaille T, McAleer R, Mendis AH, Nicholson T.  Pathogenic mechanisms underlying allergic bronchopulmonary aspergillosis (ABPA): evaluation of direct fungus‑induced epithelial damage.  Am Rev Respir Dis 1989; 4: A465.

42.   Rose AH, Bowman R, Musk AW, Neates N, Hayes A,. Robinson BWS  Evidence of alveolitis with gamma interferon (IFNY) and tumour necrosis factor alpha (TNFSYMBOL 103 \f "Pres Elite Symbol (M7)") production in asbestos‑exposed individuals who have normal chest x‑rays. Am Rev Respir Dis 1989; 4: A554.

43.   Bowman R, Manning L, Davis M, Musk AW, Robinson BWS.  Susceptibility of cultured human mesothelioma cells to lysis by drugs and cytokines.  Proc Am Assoc Cancer Res 1989; 30:611.

44.   Rose A, Bowman R, Musk AW, Neates N, Hayes A,. Robinson BWS  Alveolitis and cytokine production in asbestos‑exposed individuals who have normal chest x‑rays.  Aust NZ J Med 1989; 19(5): 643.

45.   Bowman R, Manning L, Davis M,. Robinson BWS. Sensitivity of malignant mesothelioma to drugs and cytokines. Aust NZ J Med 1989; 19(5): 651.

46.   Bowman R, Manning L, Davis M, Musk AW, Robinson BWS.  Susceptibility of cultured human mesothelioma cells to lysis by drugs and cytokines.  Proc Am Assoc Cancer Res 1989: 30:611.

47.   Manning LS, Garlepp MJ, Christmas TI, Davis MR,. Robinson BWS  In vitro effect(s) of interferons on human malignant mesothelioma cell susceptibility to cytotoxic cells and MHC expression.  Am Rev Respir Dis 1990; 141(4):A100.

48.   Christmas TI, Musk AW,. Robinson BWS  Phase II Study of recombinant human alpha interferon therapy in malignant pleural mesothelioma.  Proc Am Assoc Cancer Res 1990; 31:1678.

49.   Garlepp MJ, Manning LS, Christmas T, Davis M,. Robinson BWS  Constitutive and inducible HLA antigen expression in malignant mesothelioma.  Proc Am Assoc Cancer Res 1990; 31:1528.

50.   Garlepp MJ, Christmas TI, Manning LS, Davis MR,. Robinson BWS  HLA antigen expression in human malignant mesothelioma (MM).  Conference on Lung Cancer, Melbourne 1991.  Lung Cancer 1991;7:167

51.   Robinson BWS, Bowman RV, Christmas TI, Manning LS, Musk AW.  Clinical experience using immunotherapy (IL‑2/LAK cells or interferon alpha‑2a) in malignant mesothelioma.  Conference on Lung Cancer, Melbourne 1991.  Lung Cancer 1991;7:172

52.   Robinson BWS, Davis M, Garlepp MJ, Marzo A, Whitaker D, Manning LS.  Evaluation of mesothelioma immunogenicity.  Conference on Lung Cancer, Melbourne 1991.  Lung Cancer 1991;7:172

53.   Davis M, Manning LS, Whitaker D, Mutsaers SE,. Robinson BWS A murine model of mesothelioma.  Conference on Lung Cancer, Melbourne 1991.  Lung Cancer 1991;7:168

54.   Garlepp MJ, Christmas TI, Manning LS, Mutsaers S, Dench J,. Robinson BWS  The role of platelet derived growth factor in the growth of human malignant mesothelioma (MM).  Conference on Lung Cancer, Melbourne 1991.  Lung Cancer 1991;7:167

55.   Mavaddat N, Robinson BWS , Rose AH, Manning LS, Garlepp MJ.  Gamma delta T‑cell cytotoxicity towards malignent mesothelioma cell lines.  Aust NZ J Med 1991;21:645

56.   Robinson BWS Christmas TI, Garlepp MJ, Manning LS,.  Platelet‑derived growth factor (PDGF) as an autocrine growth factor for malignant mesothelioma.  Aust NZ J Med 1991;21:672

57.   Rose AH, Garlepp MJ, Bowman RV,. Robinson BWS  A clonal analysis of T cells from normal human bronchoalveolar lavage (BAL) compared with blood.  Aust NZ J Med 1991;21:672

58.   Fitzpatrick DR, Garlepp MJ, Mutsaers SE, Davis MR, Bielefeldt-Ohmann,. Robinson BWS  Transforming growth factor - beta: autocrine and paracrine roles in malignent mesothelioma.  Am Rev Respir Dis 1993;147:A231 .

59.   Robinson BWS, Dench JE, Rose AH, Bielefeldt-Ohmann H.  Monocytes and alveolar macrophages from patients with sarcoidosis express heat shock/stress proteins.  Am Rev Respir Dis 1993;147:A789.

60.   Dench JE, Bielefeldt-Ohmann, Rose AH, Currie B,. Robinson BWS  Serum reactivity to HSP-65 in sarcoidosis patients.  Am Rev Respir Dis 1993;147:A789.

61.   Upham JW, Robinson BWS, Holt PG.  Alveolar macrophages and T-cell activation: differential regulation of activation, cytokine production and proliferation.  Am J Resp Dis, 1994:A263.

62.   Upham JW., Holt BJ., Yabuhara A., Thomas WR., O'Keefe P., Palmer L., LeSouef P., Sly PD., Robinson BWS., Holt PG.  T cell reactitivity to allergens in atopic & normal subjects: covert in-vitro responses unmasked by serum free medium.  Am J Resp Crit Care Med, 1995:A214.

63.   Fitzpatrick DR., Bielefeldt-Ohmann H., Himbeck RP., Jarnicki AG., Marzo AL.,. Robinson BWS  Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF-SYMBOL 98 \f "Symbol" antisense RNA transfectants in a mesothelioma model. Am J Resp Crit Care Med, 1995:A671.

64.   Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS.,. Robinson BWS  A murine model of mesothelioma - pathology, immunology and biology. Am J Resp Crit Care Med, 1995:A571.

65.   Davidson JA., Musk AW.,. Robinson BWS  Intralesional cytokine therapy in cancer: a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. Am J Resp Crit Care Med, 1995:A848.

66.   Leong CC., Marley JV., Garlepp MJ.,. Robinson BWS  The gernation of antitumour immune response to murine meosthelioma by the transfection of B7-1. Am J Resp Crit Care Med, 1995:A124

67.   Venaille TV., Upham J.,. Robinson BWS  Does asthmatic epithelium lack expression of 'normal' immunoregulatory genes? - evaluation of bronchial brushings using SQ-PCR. Am J Resp Crit Care Med, 1995:A776.

68.   Jarnicki A., Fitzpatrick D., Himbeck R., Marzo A.,. Robinson BWS, Bielefeldt-Ohmann H.  Cytokine expression by tumour infiltrating lymphocytes during tumour growth-immunodeviation as a means of immuno-evasion? Am J Resp Crit Care Med, 1995:A36.

69.   Mutsaers SE, Dawson JS, Versnel MA, Robinson BWS , Laurent GJ, McAnulty RJ.  Increased procollagen production by mesothelioma cells compared with normal mesothelial cells and their response to TGF-b.  Am J Resp Crit Care Med, 1997:155(4);A762.

70.   Marzo AL, Fitzpatrick, DR, Scott BM,. Robinson BWS  Blockade of tumour-derived TGF-b in vivo using antisense oligonucleotides.  Am J Resp Crit Care Med, 1997;155(4)A462.

71.   Robinson BWS, Mukherjee S, Davidson A, Morey S, Musk AW, Ramshaw I, Smith D, Lake R, Haenel T, Garlepp M, Marley J, Leong C, Caminschi I, Scott B.  Intratumoral cytokines generated by gene transfer or by infusion in solid tumours in humans and mice.  Am J Resp Crit Care Med, 1997;155(4)A462.

72.   Mukherjee S, Nelson D, Leong C, Marley J, Garlepp M,. Robinson BWS  Vaccination with tumor cytokine transfectants delays growth but does not produce tumor eradication in a murine model of advanced malignancy.  American Journal of Resp Critical Care Med 1999.

73.   Marzo AL, Lake RA, Callow M, Lo D, Sherman L, Robinson BWS , Scott B.  Tumor antigens are constitutively presented in the draining lymph nodes.  American Journal of Resp Critical Care Med 1999.

74.   Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hacel G, Buck M, de Klerk NH,. Robinson BWS  Cisplatin and gemcitabine treatment for malignant mesothelioma (MM): a phase II study.  American Journal of Resp Critical Care Med 1999.

75.   Robinson BWS, Mukherjee S, Jackaman C, Lake R, Ramshaw I, Haenel T, Smith D, Musk A, Morey S, van Hagen D, Himbeck R, Scott B, Harnett G, Stumbles P, Davidson J, van Bruggen I, Nelson D.  Poxvectors for tumour immunotherapy – studies in mice and humans.  J of Gene Med.  2001.

Abstracts Published in Meeting Proceedings Only

1.                   Robinson BWS, Crystal RG.  Production of gamma interferon by human lung immune cells.  Australian Society for Immunology, 14th Annual Meeting, 1984.

2.                   Robinson BWS, Pinkston P, Crystal RG.  Natural killer cells are inactive in the normal human lung but can be activated with interleukin‑2.  Australian Society for Immunology, 14th Annual Meeting, 1984.

3.                   Robinson BWS.  The activity of human NK cells is directly suppressed by absestos.  Australian Society for Immunology, 14th Annual Meeting, 1984.

4.                   Robinson BWS, Morstyn G.  Human natural killer (NK) cells can be activated by recombinant interleukin‑2 (IL‑2) to destroy lung cancer cell targets.  First Combined Meeting Australian Society for Immunology/New Zealand Society for Immunology 1985.

5.                   Robinson BWS, Morstyn GW.  Human lung cancer cells can be destroyed by interleukin 2‑activated blood and lung natural killer cells.  Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1985

6.                   Robinson BWS.  NK activity against lung cancer cells.  Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.

7.                   Robinson BWS.  Human lung interstitial cells.  Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.

8.                   Robinson BWS.  Bronchoalveolar lavage studies of cell subpopulations and lymphokine production in different lung diseases.  Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.

9.                   Hayes A, Robinson BWS.  Neutrophil chemotaxis in asbestosis.  Cell Biology of the Lung Satellite Symposium, Thoracic Society of Australia, 1986.

10.               Robinson BWS, Rose AH, Hayes A, James A, Musk AW.  An active neutrophil alveolitis underlies pulmonary asbestosis.  Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1986.

11.               Robinson BWS, Venaille T.  Development of an epithelial cell‑basant membrane model for evaluation of epithelial cell detachment in asthma.  Asthma Foundation of Western Australia Annual Scientific Meeting, 1986.

12.               Robinson BWS, Rose AH, Musk AW.  Lung cells from some patients with chronic non‑granulomatous interstitial lung diseases spontaneously release gamma interferon.  6th International Congress of Immunology, Toronto, 1986.

13.               Bowman R, Manning L, Robinson BWS.  The effects of recombinant human TNF on lymphocyte‑mediated lysis of cultured and fresh human cancer cells.  Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1987

14.               Robinson BWS, Venaille T, Mendis AH, Vincent G, Blum R.  Inflammation and epithelial cell damage in asthma.  Royal Australasian College of Physicians (WA Branch) Annual Scientific Meeting, 1987

15.               Whitehead P, Robinson BWS.  Oncogenes in lung cancers.  Thoracic Society of Australia Cell Biology Symposium, 1987.

16.               Robinson BWS.  The role of inflammatory cell‑mediated epithelial cell damage in asthma.  Thoracic Society of Australia Cell Biology Symposium, 1987.

17.               Venaille T, Mendis AH, Robinson BWS.  Evaluation of neutrophil and eosinophil‑mediated epithelial cells.  Asthma Foundation of Western Australia Annual Scientific Meeting, 1987.

18.               Manning L, Robinson BWS.  Human malignant mesothelioma cells are susceptible to lysis by interleukin‑2‑activated lymphokine‑activated killer (LAK) cells.  Cancer Research Association of WA Inaugural Scientific Symposium, 1987.

19.               Flexman J, Manning L, Robinson BWS.  Augmentation of lung natural killer (NK) cell activity by administration of recombinant interleukin‑2 (IL‑2): Comparison of different routes of administration.  Cancer Research Association of WA Inaugural Scientific Symposium, 1987.

20.               Bowman R, Manning L, Robinson BWS.  Tumour necrosis factor (TNF) boosts lymphocyte‑mediated lysis of cultured and fresh human cancer cells.  Cancer Research Association of WA Inaugural Scientific Symposium, 1987.

21.               Manning LS, Musk A, Robinson BWS.  Patients with malignant mesothelioma (MM) demonstrate depressed lymphokine‑activated killer (LAK) cell activity: effect of indomethacin (INDO).  Australian Society for Immunology Annual Meeting 1988.

22.               Manning L, Bowman R, Darby S, Robinson BWS.  Preclinical investigation of the susceptibility of malignant mesothelioma (MM) to lymphokine‑activated killer (LAK) cell cytolysis.  Australian Society for Immunology Annual Meeting 1988.

23.               Bowman R, Manning L, Robinson BWS.  Effects of recombinant human tumour necrosis factor (TNF) on lymphocyte mediated lysis of mesothelioma cells.  Australian Society for Immunology Annual Meeting 1988.

24.               Rose AH, Bowman R, Musk AW, Robinson BWS.  Gamma interferon (IFN SYMBOL 103 \f "Pres Elite Symbol (M7)") and tumour necrosis factor (TNF) release in individuals exposed to asbestos.  Australian Society for Immunology Annual Meeting 1988.

25.               Robinson BWS, Mendis A, Venaille T.  Inflammatory cell‑mediated epithelial cell damage in asthma.  Australian Society for Immunology Annual Scientific Meeting, Brisbane 1988.

26.               Mendis AH, Venaille T, Robinson BWS.  Proteases mediating epithelial cell damage.  Asthma Foundation of Western Australia Annual Scientific Meeting, 1988.

27.               Robinson BWS, Venaille T, McAleer R, Mendis AH, Nicholson T.  Proteases in allergic diseases: evidence of direct allergen‑mediated tissue damage.  Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.

28.               Manning LS, Davis MR, Robinson BWS.  Asbestos exposure significantly inhibits lymphokine‑activated killer cell (LAK) function in vitro.  Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.

29.               Robinson BWS, Bowman R, Musk AW, Neates N, Hayes A.  Evaluation of T‑cell and macrophage cytokine release as early markers of human lung disease.  Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.

30.               Garlepp MJ, Manning LS, Christmas TI, Davis MR, Robinson BWS.  Heterogeneity of constitutive and inducable MHC antigen expression in malignant mesothelioma.  Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.

31.               Bowman RV, Davis MR, Manning LS, Robinson BWS.  In vitro assessment of the susceptibility of cultured human malignant mesothelioma cells to the direct anti‑proliferative effects of recombinant human cytokines and chemotherapeutic drugs.  Australian Society for Immunology Annual Scientific Meeting, Adelaide 1989.

32.               Robinson BWS, Venaile T, Mendis AH, McAleer R.  Aspergillus‑derived proteases and epithelial cell damage.  Asthma Foundation of Western Australia Annual Scientific Meeting, 1989.

33.               Robinson BWS, Rose AH, Bowman R.  Cytokine release as an early marker of pulmonary asbestosis.  Proceedings 7th International Congress of Immunology, Berlin, 1989.

34.               Manning LS, Davis M, Robinson BWS.  Asbestos fibres suppress lymphokine‑activated killer cell generation.  Proceedings 7th International Congress of Immunology, Berlin, 1989.

35.               Manning LS, Davis MR,  Robinson BWS.  Asbestos significantly inhibits lymphokine‑activated killer (LAK) cell function in vitro.  Cancer Research Association of WA Symposium 1989.

36.               Bowman RV, Manning LS, Davis MR, Musk AW, Robinson BWS.  Susceptibility of cultured human malignant mesothelioma cells to cytotoxic drugs, cytokines and immune effector cells: in vitro assessment.  Cancer Research Association of WA Symposium 1989.

37.               Manning LS, Christmas TI, Robinson BWS.  Efficacy of interferon alpha in the treatment of malignant mesothelioma.  Combined Biological Sciences Scientific Meeting, 1990.

38.               Garlepp MJ, Rose AH, Robinson BWS, Manning LS.  Susceptibility of mesothelioma cells to lysis by a TcR‑d1 positive T‑cell clone.  Proceedings of the American Association for Cancer Research Special Conference on the Molecular Basis of tumour immunology, Virginia 1990.

39.               Manning LS, Christmas TI, Robinson BWS.  Efficacy of interferon alpha (IFNa) in the treatment of malignant mesothelioma.  Proceedings of the International Conference on Biological Treatment of Melanoma and Other Cancer, Newcastle 1990.

40.               Mavaddat N, Rose AH, Manning LS, Robinson BWS, Garlepp MJ.  Gamma delta T‑cell cytotoxicity toward malignant mesothelioma cell lines.  Australian Society for Immunology Annual Scientific Meeting, Melbourne December 1990.

41.               Rose AH, Garlepp MJ, Bowman RV, Robinson BWS.  Characterisation of T‑cell clones from bronchoalveolar lavage from normal humans: comparison with blood.  Proceedings of the Australian Society for Immunology Annual Scientific Meeting, Melbourne December 1990.

42.               Rose AH, Garlepp MJ, Robinson BWS.  Clonal analysis of CD4+ T lymphocytes in sarcoidosis.  Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p52

43.               Manning LS, Davis M, Garlepp MJ, Marzo A, Whitaker D, Robinson BWS.  Evaluation of immunogenicity of mouse mesothelioma cells by immunization.  Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p77

44.               Richardson DR, Turner KJ, Robinson B.  The mechanism(s) of IgE uptake by human macrophages and A B‑lymphoblastoid cell line (WIL‑2WT): A preliminary report.  Proceedings, 21st Annual Scientific Meeting of the Australian Society for Immunology, Dec 1991 p66

45.               Dench JE, Rose AH, Robinson BWS, Bielefeldt-Ohmann H.  Mononuclear phagocytic cells from patients with sarcoidosis express heat shock proteins.  Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p57

46.               Dench JE, Bielefeldt-Ohmann H, Rose AH, Currie B, Robinson BWS.  Patients with sarcoidosis express reactivity to a 65-kilodalton heat shock protein.  Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p58

47.               Rose AH, Dench JE, Garlepp MJ, Robinson BWS.  Clonal analysis of bronchoalveolar lavage (BAL) T-cells in interstitial lung disease (ILD).  Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p64

48.               Bielefeldt-Ohmann H, Marzo A, Davis M, Fitzpatrick DR, Robinson BWS.  In situ phenotyping of mononuclear cell infiltrates in experimental malignant mesothelioma: a marker of host responses?  Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p84

49.               Fitzpatrick DR, Garlepp MJ, Mutsaers SE, David MR, Bielefeldt-Ohmann H, Robinson BWS.  Transforming growth factor-beta: autocrine and paracrine roles in malignant mesothelioma.  Proceedings Australasian Society for Immunology 22nd Annual Scientific Meeting, Auckland, New Zealand 2-4 December 1992 p85

50.               Upham JW, Bilyk N, Robinson B, Holt P.  Does nitric oxide mediate the immunosuppressive activity of alveolar macrophages?  Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 028.

51.               Fitzpatrick DR, Garlepp MJ, Mutsaers SE, Davis MR, Bielefeldt-Ohmann, Robinson BWS.  Transforming growth factor - Beta: autocrine and paracrine roles in malignant mesothelioma?  Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 026.

52.               Robinson BWS, Leong CC, Garlepp MJ.  Inoculation of allogeneic MHC transfectants does not confer immunity to the parental mesothelioma cell line.   Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, 027.

53.               Dench A, Rose A, Bielefeldt-Ohmann H, Robinson B.  A potential role for stress proteins in the pathogenesis of sarcoidosis.  Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting, Sydney 26-29 April 1993, P92.

54.               Jarnicki A, Fitzpatrick D, Marzo A, Robinson B, Bielefeldt-Ohmann H.  cytokine production and surface antigen profile of tumour infiltrating leukocytes (TIL) in malignant mesothelioma.  Proceedings of Clinical Oncological Society of Australia, Perth 1993, P41.

55.               Peroni D, Fitzpatrick D, Robinson B.  Inhibition of platelet-derived growth factor-A (PDGF-A) expression in malignant mesothelioma  by antisense mRNA production. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P75.

56.               Fitzpatrick D, Bielefeldt-Ohmann H, Robinson B.  Analysis of the roles of transforming growth factor-beta in the tumorigenesis of malignant mesothelioma. Proceedings of Clinical Oncological Society of Australia, Perth 1993, 76.

57.               Leong CC, Robinson B, Garlepp M.  The generation of an antitumour immune response by allogeneic MHC gene transfer. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P78.

58.               Jarnicki A, Fitzpatrick D, Marzo A, Robinson B, bielefeldt-Ohmann H.  Cytokine production and surface antigen profile of tumour infiltrating leukocytes (TIL) in malignant mesothelioma. Proceedings of Clinical Oncological Society of Australia, Perth 1993, P119.

59.               Upham J, Robinson B, Holt P.,  Alveolar macrophages and T cell activation:- differential regulation of activation, cytokine production and proliferation.  Proceedings of American Thoracic Society, Boston 21-25 May 1994.

60.               Wood-Baker R, Musk A, Morey S, Drury P, Robinson B.  Intralesional interferon treatment of malignant mesothelioma.  Proceedings Thoracic Society of Australia and New Zealand Annual Scientific Meeting,  Hamilton Island 9-14 April 1994, P212.

61.               Upham J, Robinson B, Holt P.  Alveolar macrophages and T cell activation: differential regulation of activation markers, cytokine production and proliferation.  Proceedings thoracic Society of Australia and New Zealand Annual Scientific Meeting, Hamilton Island 9-14 April 1994, P38.

62.               Upham J, Robinson B, Holt P.  The soluble form of the low affinity IgE receptor enhances allergen specific T cell proliferation.  Proceedings Thoracic Society of Australia and New Zeland Annual Scientific Meeting, Hamilton Island 9-14 April 1994, P163.

63.               Davidson JA., Musk AW., Robinson BWS.  Ideas on staging progression, and new prognostic test for mesothelioma.  European School of Lung Cancer, Medical Oncology Group meeting, Sydney, 1994.

64.               Davidson JA., Musk AW., Robinson BWS.  In vitro and in vivo effect of Taxol on mesothelioma murine and human cell lines and investigation of cremophor on mesotheliomas sensitivity to Adriamycin.  Clinical Oncology Society of Australia, Adelaide, November 1994.

65.               Davidson JA and Robinson BWS.  To evaluate the effect of granulocyte macrophage colony stimulating factor (GM-CSF) and retinoids on mesothelioma growth and any additive effect for the combination with alpha interferon.  Clinical Oncology Society of Australia, Adelaide, November 1994.

66.               Marzo AL., Fitzpatrick DR., Robinson BWS.  Inhibition of malignant mesothelioma (MM) growth by anti-sense oligonucleotides specific for transforming growth factor-beta (TGF-SYMBOL 98 \f "Symbol").  Australian Society of Immunology, Canberra 5-7 December, 1994.

67.               Upham J, Holt B, Yabuhara A, Thomas W, O’Keefe P, Palmer L, LeSouef P, Sly P, Robinson B, Holt P.  T-cell reactivity to allergens in atopic and normal subjects: covert in vitro responses unmasked by serum free medium.  ATS International Conference, Seattle Washington, May 21-24, 1995.

68.               Fitzpatrick DR., Bielefeldt-Ohmann H., Himbeck RP., Jarnicki AG., Marzo AL., Robinson BWS.  Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF-SYMBOL 98 \f "Symbol" antisense RNA transfectants in a mesothelioma model. ATS International Conference, Seattle Washington, May 21-24, 1995.

69.               Bielefeldt-Ohmann H., Fitzpatrick DR., Marzo AL., Jarnicki AG., Himbeck RP., Davis MR., Manning LS., Robinson BWS.  A murine model of mesothelioma - pathology, immunology and biology. ATS International Conference, Seattle Washington, May 21-24, 1995.

70.               Davidson JA., Musk AW., Robinson BWS.  Intralesional cytokine therapy in cancer: a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. ATS International Conference, Seattle Washington, May 21-24, 1995.

71.               Leong CC., Marley JV., Garlepp MJ., Robinson BWS.  The gernation of antitumour immune response to murine meosthelioma by the transfection of B7-1. ATS International Conference, Seattle Washington, May 21-24, 1995.

72.               Venaille TV., Upham J., Robinson BWS.  Does asthmatic epithelium lack expression of 'normal' immunoregulatory genes? - evaluation of bronchial brushings using SQ-PCR. ATS International Conference, Seattle Washington, May 21-24, 1995.

73.               Jarnicki A., Fitzpatrick D., Himbeck R., Marzo A., Robinson BWS., Bielefeldt-Ohmann H.  Cytokine expression by tumour infiltrating lymphocytes during tumour growth-immunodeviation as a means of immuno-evasion? ATS International Conference, Seattle Washington, May 21-24, 1995.

74.               Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS.  Tumour-induced immunosuppression and autocrine growth: use of inducible anti TGF-b antisense RNA transfectants in a mesothelioma model.  International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

75.               Caminschi I, Jarnicki A, Fitzpatrick D, Marzo A, Himbeck R, Bundell C, Scott B, Robinson BWS, Bielefeldt-Ohmann H.  Growth of a murine malignant mesothelioma cell line in vivo: lack of immune aggression due to immune deviation. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

76.               Marley JV, Leong CC, Robinson BWS, Garlepp MJ.  Co-expression of allogeneic MHC and a co-stimulatory molecule (B7-1) augments the immune response to a mesothelioma cell line. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

77.               Leong CC, Marley JV, Robinson BWS, Garlepp MJ.  B7-1 transfection can abrogate tumour non-immunogenicity but in vivo tumour growth occurs via a decay in CTL activity. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

78.               Bielefeldt-Ohmann H, Fitzpatrick DR, Marzo Al, Jarnicki AG, Himbeck RP, Davis MR, Manning LS, Robinson BWS.  A murine model of mesothelioma - pathology, immunology and biology. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

79.               Davidson JA, Musk AW, Robinson BWS.  Intralesional cytokine therapy in cancer a phase I and II study of alpha interferon and GM-CSF infusion in mesothelioma. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

80.               Davidson JA, Robinson BWS.  In vitro and in vivo effect of Taxol on mesothelioma murine and human cell lines and investigation of cremophor effect on mesothelioma’s sensitivity to Adriamycin. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

81.               Marzo AL, Fitzpatrick DR, Scott B, Bundell C, Robinson BWS.  Antisense oligonucleotides specific for transforming growth factor-beta (TGF-b) inhibit the growth of malignant mesothelioma (MM) both in vitro and in vivo. International Mesothelioma Interest Group Conference, Paris, France, 13-15 September 1995.

82.               Marzo AL, Scott BM, Fitzpatrick D, Robinson BWS.  Antisense oligonucleotides specific for TGF-b inhibit the growth of malignant mesothelioma.  ASI Meeting 1995, Gold Coast, Queensland, Australia, 3-7 December, 1995.

83.               Caminschi I, Scott BM, Robinson BWS.  Recombinant IL-12 administration prevents the growth of a murine malignant mesothelioma cell line in vivo.  ASI Meeting 1995, Gold Coast, Queensland, Australia, 3-7 December, 1995.

84.               Caminschi I, Scott B, Garlepp M, Robinson.  Recombinant IL-12 prevents the growth of murine malignant mesothelioma.  ASI Meeting, 1996, Adelaide, South Australia, Australia, 1-5 December, 1996.

85.               Caminschi I, Venetsanakos E, Garlepp M, Robinson BWS, Scott B.  Local secretion of interluekin-12 inhibits proximal and distal tumour growth.  Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

86.               Robinson C, Callow M, Robinson BWS, Lake RA.  Tumour antigens from malignant mesothelioma. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

87.               Marzo AL, Himbeck R, Haenal T, Lake RA, Robinson BWS, Scott B.  The presence of a strong tumour antigen and specific T cells does not induce an effective anti-tumour response. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

88.               Marzo AL, Callow M, Robinson BWS, Lake RA, Scott B.  The recognition of tumour antigens by effector T cells in vivo – a role for cross priming in lymphoid organs. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

89.               Marzo AL, Fitzpatrick DR, Scott B, Robinson BWS.  Blockade of tumour-derived TGF-b using antisense oligonucleotides. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

90.               Mukherjee S, Haenel T, Epton M, Lake RA, Harnett G, Phillips P, Drury P, Morey S, Smith D, Ramshaw I, Davidson J, Musk AW, Robinson BWS.  Persistant vaccinia virus-interleukin 2 (VV-IL2) gene expression in malignant mesothelioma (MM) despite evidence of anti-viral immunity. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

91.               Venetsanakos E, Caminschi I, Chan J, Scott B, Robinson BWS.  Characterisation of resident and splenic macrophages in muine mesothelioma model. Tumour Immunology Workshop, Perth, Western Australia, Australia, 4th-6th December, 1997.

92.               McLaren BR, Robinson BWS, Lake RA.  Mesothelioma: Chemotherapy, cytokines and resistance.  NZ Society for Oncology Annual Scientific Congress, Christchurch, New Zealand, May 1998.

93.               Lake RA, Robinson BWS, Hayball JD.  MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.

94.               Hayball JD, Marzo AL, Scott BM, Robinson BWS, Lake RA.  Partial agonism of a polyclonal set of human Vb17 expressing T cell by an altered bacterial superantigen. QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.

95.               Marzo AL, Lake RA, Callow M, Robinson BWS, Scot B.  Tumour antigens are presented constitutively to tumour-specific T cells in the draining lymph nodes.  QIMR International Symposia on Molecular Medicine, Brisbane, Australia, 20th-21st August, 1998.

96.               Hayball JD, Marzo AL, Scott BM, Robinson BWS, Lake RA.  Partial agonism of a polyclonal set of human Vb17 expressing T cell by an altered bacterial superantigen. Australian Society of Immunology, Melbourne, Australia, 1st-5th December, 1998.

97.               Lake RA, Robinson BWS, Hayball JD.  MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response. Australian Society of Immunology, Melbourne, Australia, 1st-5th December, 1998.

98.               Lake RA, Robinson BWS, Hayball JD.  MHC multimerisation, antigen expression and the induction of APC amnesia in the developing immune response.  10th International Congress of Immunology, India, 1st-6th November, 1998.

99.               Marzo AL, Lake RA, Callow M, Lo D, Sherman L, Robinson BWS, Scott BM.  TCR Transgenic analysis of class I and II restricted tumour-specific T cell responses: CD8 response deficits occur distal to local antigen presentation.  Proc of Am. Assoc. for Immunologists, ASM 1999.

100.            Mukherjee S, Haenel T, Himbeck R, Scott B, Ramshaw I, Lake RA, Harnett G, Phillips P, Morey S, Smith D, Davidson JA, Musk AW, Robinson BWS.  TCR transgenic analysis of class I and II restricted tumour-vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation.  Proc of Am. Assoc. for Immunologists, ASM 1999.

101.            Robinson BWS.  Gene Therapy for Cancer.  Proc of Australasian Pharmaceutical Science Assoc, APSA.  Annual Conference 1999.

102.            Jackaman C, Bundell C, Kinnear B, van Hagen D, Robinson BWS, Nelson D.  Interleukin-2 intra-tumoral immunotherapy of malignant mesothelioma: Size does matter.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

103.            Robinson BWS, Creaney J, Lake RA, Nowak A, Musk AW, de Klerk N, Winzell P, Scholler N, Hellstrom KE, Hellstrom I.  Serum mesothelin is elevated in mesothelioma patients and can predate diagnosis.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

104.            Nowak A, Robinson BWS, Lake RA.  Gemcitabine and activating anti-CD40 antibody synergise to cure an established murine malignant mesothelioma (MM).  6th International Mesothelioma Interest Group Conference.  Perth 2002.

105.            Nowak A, Byrne MJ, Williamson R, Ryan G, Segal A, Fielding D, Mitchell P, Musk AW, Robinson BWS.  Quality of life analysis from a multicentre phase II study of cisplatin and gemcitabine in malignant mesothelioma (MM).  6th International Mesothelioma Interest Group Conference.  Perth 2002.

106.            Nelson D, Jackaman C, Bundell C, Robinson BWS.  Evaluation of tumour-specific T cell responses during progression of mesothelioma.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

107.            Van Bruggen I, Jackaman C, Caminschi I, Liu Y, Robinson BWS.  Does constant rate cytokine infusion in mesothelioma offer a better delivery regimen than repeated bolus injections?.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

108.            Smith A, van Bruggen I, Broomfield S, Himbeck R, Bundell C, Creaney J, Nelson D, Lake RA, Robinson BWS.  Autologous mesothelioma cell lysate as a source of tumour antigens for dendritic cell pulsing.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

109.            Broomfield S, van Bruggen I, Smith A, Robinson BWS.  Enhancing the immune response to mesothelioma antigens with heat shock protein enriched autologous tumour lysate.  6th International Mesothelioma Interest Group Conference.  Perth 2002.

110.            Creaney J, Robinson BWS, Musk AW, de Klerk N, Lake RA.  Identification of mesothelioma-specific antigens. 6th International Mesothelioma Interest Group Conference.  Perth 2002.

111.            Creaney J, Lake RA, Nowak A, Musk AW, Robinson BWS.  Elevated levels of mesothelin-family proteins in malignant mesothelioma. 6th International Mesothelioma Interest Group Conference.  Perth 2002.

112.            Robinson BWS, Nowak A, Marzo A, Himbeck R, Stumbles P, Frelinger J, Heath W, Scott B, Lake R.  Tumor antigen cross presentation and the impact of induction of tumor cell apoptosis in vivo on specific CD8 function and CD40 responses.  Keystone International Conference, Colorado, USA 2003.

113.            Robinson BWS, Nowak A, Marzo A, Himbeck R, Stumbles P, Frelinger J, Heath W, Scott B, Lake R.  Tumor antigen cross presentation, tumor cell apoptosis – specific CD8 and CD40 responses.  The Annual American Association of Immunology Meeting.  Denver, Colorado, USA 2003.

114.            Nelson DJ, Jackaman C, Robinson BWS, Zhan Y, Lew AM.  Intra-tumoral activating anti-CD40 requires further ‘help’ offered by intra-tumoral interleukin-2 to induce reliable and permanent regression of large, rapidly growing solid tumors.  The Annual American Association of Immunology Meeting.  Denver, Colorado, USA 2003.

115.            Nowak AK, Robinson BWS, Lake R.  Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumours.  Medical Oncology Group, RACP Australia, Annual Scientific Meeting 2003.

116.            Robinson BWS, Heath W, Nowak AJ, Frelinger J, Lake RA, Scott B, Stumbles P, Himbeck R, Marzo A.  Tumor-Specific CD8 cells are constitutively ‘cross-armed’ but only in tumor-draining nodes and are driven out of lymph nodes by CD40 stimulation.  12th International Congress of Immunology, Montreal, July 2004.

117.            Creaney J, Robinson BWS.  Serum Mesothelin-Related Protein – a new serum marker for mesothelioma.  International Mesothelioma Interest Group, Italy 2004.

118.            Brown MD, Vivian JB, Currie AJ, Price P, Robinson BWS, Hall JC.  Are Tumour Vaccines Logical? Urological Society of Australasia State Meeting (WA), Bunker Bay Western Australia November 5-7 2004.

119.            Brown MD, Vivian JB, Currie AJ, Price P, Robinson BWS, Hall JC.  Postoperative Tumour Neo-Antigen Presentation in Murine Models of Primary and Metastatic Malignancy.  Australasian Society of Immunology National Convention, Adelaide South Australia, December 12-16 2005.

120.            Brown MD, Currie AJ, Vivian JB, Robinson BWS. Postoperative Tumour Neo Antigen Presentation, Keystone Cancer Symposium, Keystone Colorado March 19-24 2005.

121.            Brown MD, Vivian JB, Currie AJ, Robinson BWS. Surgery Re-Sets the Anti-Tumour Immune Response. Urological Society of Australasia State Meeting (WA), Bunker Bay Western Australia, November 4-6 2005.

122.            Sherwood A, Creaney J, Robinson BWS, Lake R. Identification of Key Genetic Changes Involved in Mesothelial Cell Transformation. Combined Biological Sciences Meeting (CBSM), Perth Australia 2002.

123.            Sherwood A, Creaney J, Lake R, Robinson BWS. Identification of Genetic Markers for Mesothelioma. The International Mesothelioma Interest Group(IMIG) meeting, Perth, Australia 2002.

124.            Sherwood A, Robinson BWS, Nelson D, Lake R. Identification of Tumour Antigens Associated with Mesothelial Cell Transformation. Australasian Society of Immunology (ASI) meeting, Perth, Australia, 2003.

125.            Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Identification of Key Genetic Markers Associated with Mesothelial Cell Transformation. ComBio meeting, Perth, Australia 2004.

126.            Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Characterisation and Gene Profiling of an In Vitro Model of Mesothelial Cell Transformation. 4th National Microarray Conference and Inaugural Meeting of the Australasian Microarray and Associated Technologies Assoc.(AMATA), Perth, Australia 2004.

127.            Sherwood A, Mutsaers S, Robinson BWS, Nelson D, Lake R. Characterisation of an In Vitro Model of Mesothelial Cell Transformation. Keystone Symposia- Cancer and Development(J6), Banff, Alberta, Canada 2005.

128.            Creaney J, Lake R, Musk AW, de Klerk N, Robinson BWS. Soluble Mesothelin Related Protein (SMRP): A marker for Mesothelioma. Molecular and Cell Biology of Cancer, Melbourne, November 14-16 2005.

129.            Creaney J, Lake R, Robinson BWS. Ribonucleotide reductase: levels in malignant mesothelioma. Cancer Knowledge - Cancer practise: The fifth WA State Cancer Conference, Perth October 18, 2005.

130.            Sherwood A, Robinson BWS. Profiling of an In Vitro Model of Mesothelial Cell Transformation. The fifth WA State Cancer Conference, Perth October 18, 2005.

131.            Mutsaers S, Robinson BWS, Nelson D, Lake R. Keystone Symposia-Stem Cells, Senescence and Cancer(D5), Singapore 2005.

132.            Robinson BWS, Creaney J. Mesothelioma- serum markers- potential value in diagnosis, monitoring and screening. The Thoracic Society of Australia and New Zealand, Perth March 20-23 2005.

133.            Creaney J, Segal A, Musk AW, De Klerk NH & Robinson BWS. Potential biomarker for mesothelioma. 36^th Annual Scientific and Business Meeting of the Australian Society of Cytology, November 2006, Perth Western Australia.

134.            Robinson BWS, Creaney J, Segal A, Musk AW, De Klerk N, Skates SJ & Pass HI. Biomarkers for early detection of asbestos-induced cancer. Gordon 0Conference. January 2007.

135.            Creaney J & Robinson BWS. Biomarkers in malignant mesothelioma. Thoracic Society of Australia and New Zealand, April 2007.

136.            McDonnell, AM, Prosser, AC, Van Bruggen, I, Currie, AJ & Robinson BWS. Cross presentation of tumour antigens from tumour dendritic cells is blocked. TSANZ ASM 2008.

137.            Creaney J, Boudville N, Musk AW, Segal A and Robinson BWS. Screening for mesothelioma using serum v urine mesothelin levels. TSANZ ASM 2008.

138.            Robinson BWS, Currie AJ, Brown M, Lake R, Nowak A. Synergism between immunotherapy and conventional chemotherapy and surgery for lung malignancies. TSANZ ASM 2008.

139.            Broomfield S, Van der Most R, Prosser A, Mahendran S, Robinson BWS, Currie A. Human and mouse tumors express TLR7: evidence for in-vivo sensitivity to local treatment with Imiquimod. TSANZ ASM 2008.

140.            McDonnell AM, Prosser AC, Van Bruggen I, Currie AJ, Robinson BWS. Cross presentation of tumour antigens from tumour dendritic cells is blocked. ATS ASM 2008.

141.            Creaney J, Boudville N, Musk AW, Segal A, Robinson BWS. Screening for mesothelioma using serum v urine mesothelin levels. ATS ASM 2008.

142.            Robinson BWS, Currie AJ, Brown M, Lake R, Nowak A. Synergism between immunotherapy and conventional chemotherapy and surgery for lung malignancies. ATS ASM 2008.

143.            Broomfield S, Prosser A, Van der Most R, Mahendran S, Robinson BWS, Currie AJ. Locally adminstered toll-like receptor 7 agonists drive systemic anti-tumour immune responses that are enhanced by anti-CD40 immunotherapy. Australian Society for Medical Research - Medical Research Week Symposium 2008. Curtin University, Bentley, Western Australia. (Oral presentation).

144.            Broomfield S, Prosser A, Van der Most R, Mahendran S, Robinson BWS, Currie AJ. A locally administered toll-like receptor-7 agonist drives systemic anti-tumour immune responses that are enhanced by anti-CD40 immunotherapy. Toll 2008 Conference, Lisbon, Portugal. (Poster presentation).

145.            Creaney J, Segal A, Nowak AK, Francis RJ, Alvarez J, Musk AW, Robinson BWS. The use of mesothelin for monitoring patients with mesothelioma. International Mesothelioma Interest Group Meeting. Amsterdam 2008. (Oral presentation)

Return to resume